课题基金 / 基金详情

基于超声影像方法研究肠道菌群与甲状腺VEGF表达的联合干预对改善桥本甲状腺炎的作用

批准号:
82071952
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
李苗
依托单位:
学科分类:
超声医学
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
李苗

项目摘要

结项摘要

李苗的其他基金

相似基金

相关文献

中文摘要
研究表明肠道菌群与甲状腺VEGF表达均可影响甲状腺功能和免疫炎症,但干预它们对改善桥本甲状腺炎(HT)的效果和作用尚不清楚。在前期研究中,我们发现HT患者双歧杆菌属和乳杆菌属明显减少,血液VEGF水平显著升高,HT大鼠血液VEGF水平和甲状腺VEGF表达水平也明显升高。基于此,我们提出双歧杆菌属和乳杆菌属的某些特征菌种减少和甲状腺VEGF表达升高共同影响甲状腺功能并加重其炎症浸润,从而参与HT的发生发展。本研究将肠道菌群干预与超声靶向微泡破裂(UTMD)介导的甲状腺VEGF表达干预相结合,利用超声影像学、微生物学、生物化学与分子生物学等手段,从人群和动物两个层面,兼顾甲状腺形态/组织硬度/血流/炎性反应与肠道菌群和VEGF表达的交互效应,拟围绕肠道菌群与UTMD介导的甲状腺VEGF表达的联合干预对改善HT的效果进行研究,阐明其在改善甲状腺功能和免疫炎症中的作用,为HT的早期防治提供新思路。
英文摘要
Previous studies suggested that alteration of gut microbiota and changes in VEGF expression in thyroid gland would affect thyroid function and its immune inflammation, but the effects of regulating them on improving Hashimoto's thyroiditis (HT) remain unknown. In previous experiments, we identified that Bifidobacterium and Lactobacillus genera in HT patients were significantly reduced, blood VEGF levels in HT patients were significantly increased, and blood VEGF levels and thyroid VEGF expression levels in HT rats were also significantly increased. Based on the pre-experimental results of populations and animals, we propose that the reduction of certain specific species of Bifidobacterium and Lactobacillus genera in gut microbiota and the increased expression of VEGF in the thyroid gland would affect the thyroid function and increase its inflammatory infiltration, thereby participating in the development of HT. The proposal will first analyze gut microbiota and VEGF levels in strictly matched case-control samples to identify the specific species in Bifidobacterium and Lactobacillus genera and the changes in VEGF levels. Then, the correlation analyses of thyroid morphology, blood flow, tissue hardness, and function will be performed between each subgroup of HT patients and between them and healthy control group, in order to determine the relationships between specific species, VEGF levels, thyroid morphology, blood flow, tissue hardness, and function. Finally, the innovative joint interventions of specific species in gut microbiota and VEGF expression mediated by ultrasound-targeted-microbubble-destruction (UTMD) in thyroid gland would be conducted in HT rats. Based on three aspects in thyroid (thyroid morphology / blood flow / tissue hardness and thyroid function and thyroid inflammatory), together with the interactive associations of them with specific species in gut microbiota and VEGF expression, the effects of joint interventions of specific species in gut microbiota and VEGF expression mediated by UTMD in thyroid gland on improving HT would be verified. These will clarify their roles in improving thyroid function and immune inflammation levels, and provide new methods and new ideas for the early prevention and treatment of HT.
桥本甲状腺炎(HT)是一种常见的器官特异性自身免疫性疾病,其早期发病机制复杂且诊断困难,严重影响患者生活质量。本项目围绕HT早期诊断和防治中的关键科学问题,创新性地采用多组学整合分析方法,系统研究其发病机制和早期分子标志物,旨在为疾病的早期诊断和精准防治提供新策略。项目针对HT患者及健康对照组进行了系统性的肠道菌群测序和转录组测序分析,成功建立了多组学数据整合分析平台。研究首次系统揭示了早期HT患者的特征性肠道菌群改变谱,发现了三个具有重要诊断价值的特征菌种,并通过整合分析明确了关键调控RNA分子及其互作网络。基于这些发现,项目创新性地构建了早期HT诊断模型,模型诊断效能良好,AUC值达到0.88。特别重要的是,研究首次阐明了肠-甲状腺轴在HT发病过程中的作用机制,为深入理解疾病发生发展提供了新的研究视角和理论基础。项目成果共发表SCI收录论文2篇:一篇系统报道了基于肠道菌群与宿主转录组的整合分析结果,阐明了肠-甲状腺轴在HT发病中的关键作用;另一篇创新性地报道了基于转录组分析的分子特征识别及机器学习模型构建成果。项目建立的多组学分析方法和早期诊断模型具有重要的应用价值,为后续临床转化研究奠定了坚实基础。研究成果在理论层面系统揭示了HT发病过程中肠-甲状腺轴的调控机制,显著丰富了对疾病发病机制的认知;在实践层面提供了基于肠道菌群的无创早期诊断新方法和分子标志物,为个体化精准治疗提供了创新性思路。这些发现不仅推动了该领域基础研究的纵深发展,也为HT的临床诊疗提供了新的策略和方向。目前,项目成果已进入基础研究向临床转化的过渡阶段,展现出良好的应用转化前景。
UTMD介导基于CRISPR/Cas9技术的靶向SEPS1基因敲除实现桥本氏甲状腺炎基因治疗的研究
  • 批准号:
    81701717
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    李苗
  • 依托单位:
国内基金
海外基金